A new trading day began on Monday, with Syros Pharmaceuticals Inc (NASDAQ: SYRS) stock price up 23.75% from the previous day of trading, before settling in for the closing price of $2.61. SYRS’s price has ranged from $1.43 to $8.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 128.79%. Meanwhile, its annual earnings per share averaged 72.91%. With a float of $19.70 million, this company’s outstanding shares have now reached $26.45 million.
Let’s determine the extent of company efficiency that accounts for 68 employees. In terms of profitability, gross margin is -228.76%, operating margin of -28892.23%, and the pretax margin is -25340.67%.
Syros Pharmaceuticals Inc (SYRS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Syros Pharmaceuticals Inc is 26.57%, while institutional ownership is 55.74%. The most recent insider transaction that took place on Sep 11 ’24, was worth 85,420. In this transaction President & CEO of this company bought 50,000 shares at a rate of $1.71, taking the stock ownership to the 122,504 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Financial Officer bought 45,344 for $1.68, making the entire transaction worth $76,006. This insider now owns 124,552 shares in total.
Syros Pharmaceuticals Inc (SYRS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 72.91% per share during the next fiscal year.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Trading Performance Indicators
Here are Syros Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 226.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.72 in the next quarter and is forecasted to reach -2.66 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc (SYRS)
Looking closely at Syros Pharmaceuticals Inc (NASDAQ: SYRS), its last 5-days average volume was 0.41 million, which is a jump from its year-to-date volume of 0.25 million. As of the previous 9 days, the stock’s Stochastic %D was 79.47%. Additionally, its Average True Range was 0.28.
During the past 100 days, Syros Pharmaceuticals Inc’s (SYRS) raw stochastic average was set at 32.74%, which indicates a significant decrease from 88.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 142.93% in the past 14 days, which was lower than the 178.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.04, while its 200-day Moving Average is $4.61. However, in the short run, Syros Pharmaceuticals Inc’s stock first resistance to watch stands at $3.54. Second resistance stands at $3.86. The third major resistance level sits at $4.31. If the price goes on to break the first support level at $2.77, it is likely to go to the next support level at $2.32. Should the price break the second support level, the third support level stands at $2.00.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Key Stats
With a market capitalization of 88.36 million, the company has a total of 26,832K Shares Outstanding. Currently, annual sales are 9,940 K while annual income is -164,570 K. The company’s previous quarter sales were 0 K while its latest quarter income was -6,400 K.
